Background: CDC25 phosphatases control cell cycle progression by activating cyclin dependent kinases. The three CDC25 isoforms encoding genes are submitted to alternative splicing events which generate at least two variants for CDC25A and five for both CDC25B and CDC25C. An overexpression of CDC25 was reported in several types of cancer, including breast cancer, and is often associated with a poor prognosis. Nevertheless, most of the previous studies did not address the expression of CDC25 splice variants. Here, we evaluated CDC25 spliced transcripts expression in anti-cancerous drug-sensitive and resistant breast cancer cell lines in order to identify potential breast cancer biomarkers. Methods: CDC25 splice variants mRNA levels were evaluated by semi-quantitative RT-PCR and by an original realtime RT-PCR assay. Results: CDC25 spliced transcripts are differentially expressed in the breast cancer cell lines studied. An up-regulation of CDC25A2 variant and an increase of the CDC25C5/C1 ratio are associated to the multidrug-resistance in VCREMS and DOXOR breast cancer cells, compared to their sensitive counterpart cell line MCF-7. Additionally, CDC25B2 transcript is exclusively over-expressed in VCREMS resistant cells and could therefore be involved in the development of certain type of drug resistance. Conclusions: CDC25 splice variants could represent interesting potential breast cancer prognostic biomarkers.
Introduction
A wide variety of cancers present abnormal expression of cell cycle regulatory proteins related to the malignant transformation of cells. The most important effectors of the cell cycle control belong to the cyclins and cyclin dependent kinase (CDK) family. Different cyclin/CDK complexes are sequentially activated and inactivated throughout cell cycle progression. CDK activity is regulated, among other mechanisms, by phosphorylation of two residues located within the ATP binding site (Thr14 and Tyr15 of CDK1). The phosphorylation of these residues by the WEE1 and MYT1 kinases maintains CDK to an inactive form (1), whereas their dephosphorylation by CDC25 phosphatases activates CDK, allowing progression into the next phase of the cell cycle (2) .
CDC25 phosphatases are essential for cell cycle control in eukaryotes under normal conditions and in response to DNA damage (3) . The N-terminal regulatory domain is involved in a tight regulation of CDC25 by multiple mechanisms, including phosphorylation, protein interactions (14-3-3) , changes in their intracellular localization, and proteasomemediated degradation (4) . Three isoforms of CDC25 were identified in humans: CDC25A, CDC25B, and CDC25C. CDC25A was initially found to act mainly at the G 1 /S transition (5), while CDC25B and CDC25C were preferentially required at the G 2 /M transition (6, 7) . However, recent studies suggest a functional redundancy of the three CDC25 isoforms both at the G 1 /S and G 2 /M transitions (8) . Previously, CDC25A and CDC25B, but not CDC25C, were described as potential oncogenes as they cooperate either with expression of HRAS or loss of RB1 to induce oncogenic transformation in murine fibroblasts (9) . Consistent with this potential oncogenic role, CDC25A and CDC25B over-expression was reported in a variety of human cancers, such as breast (9) (10) (11) (12) (13) (14) , ovarian (15) , colorectal (16) , esophageal (17) , and non-small cell lung carcinomas (18) , or in non-Hodgkin's lymphomas (19) . Furthermore, this over-expression was frequently correlated with a more aggressive form of tumor and with a poor prognosis (20) . Conversely, CDC25C overexpression has been observed in a limited number of cancers (16, 21, 22) . However, the over-expression of CDC25, in particular CDC25C, could be misestimated in many of those studies due to the non-discrimination between alternative splice variants.
Indeed, the three CDC25 isoforms are submitted to an alternative splicing mechanism occurring at the N-terminal regulatory domain which generates at least two variants for CDC25A (23) and five for both CDC25B (24, 25) and CDC25C (23, 26) (Figure 1 ). All CDC25 splice isoforms keep an intact catalytic domain, except CDC25C3 which gives rise to a truncated protein, lacking the phosphatase activity (23) . This alternative splicing leads to the loss of consensus regulatory sites that might modulate the ability of each spliced protein to regulate the cell cycle. Little is known until now about the specific functions of each CDC25 splice variant, their expression in tumors, and their potential role in oncogenesis. More precisely, to our knowledge, no expression study of these variants in breast cancer has been reported so far. As disruption of the splicing process is a recurrent phenomenon during tumorigenesis (27) , alternatively spliced transcripts can represent valuable cancer biomarkers (28) . Therefore, the aim of our study was to evaluate CDC25 splice variants mRNA expression in breast cancer cell lines in order to identify potential breast cancer biomarkers. Moreover, evaluating the expression of CDC25 splice variants in sensitive and resistant cell lines may help to understand the role of these variants in cancer progression.
Materials and methods

Cell lines and cell culture conditions
MCF-7 (ECACC, Salisbury, UK, 86012803) (29) , VCREMS (30) , and MDA-MB231 (ATCC, Manassas, VA, HTB-26) (31) cell lines were grown in RPMI-1640 medium (Eurobio, Les Ulis, France) supplemented with 10% (v/v) fetal bovine serum, 2 mmol/L glutamine, and 100 UI/mL penicillin/100 mg/mL streptomycin at 378C in a humidified atmosphere containing 5% CO 2 . DOXOR cells (initially denoted Adr R ) (32) were cultured in the same conditions in the presence of 9 mmol/L doxorubicin to maintain their resistance phenotype. hTERT-HME1 cell line (ATCC, CRL-4010) was maintained in 90% of the medium mentioned above and 10% of MEGM medium (Cambrex, Walkersville, MD). The cells were plated at a density of 1.10 6 in 100-mm dishes and then harvested in exponential growing phase.
RNA isolation and cDNA synthesis
Total RNA was extracted using Extract-All reagent (Eurobio) following the manufacturer's instructions and treated with RNase-free DNase I (Qiagen, Courtaboeuf, France) to eliminate genomic DNA. RNA was quantified and checked for integrity by means of agarose gel electrophoresis. For subsequent semi-quantitative RT-PCR experiments, 2 mg of total RNA were used to synthesize cDNA. RNA was first incubated with oligodT (10 mmol/L), heated for 10 min at 708C, cooled for 5 min on ice and then incubated for 1 h at 428C in the presence of 400 units of Maloney murine leukemia virus reverse transcriptase (Promega, Charbonnières-les-Bains, France), 1.2 U/mL RNase inhibitor, and 500 mmol/L dNTP. For real-time RT-PCR assays, cDNA was obtained using the TaqMan ᭨ Reverse Transcription Reagent kit with random hexamers (Applied Biosystems, Courtaboeuf, France) as described in the manufacturer's protocol.
Semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis
PCRs were performed using 100 ng of cDNA prepared as described above, in a total volume of 25 mL. PCR experiments specific for each CDC25 variant were performed using the following primer pairs (see Figure 1 
Real-time quantitative RT-PCR
The mRNA level of each CDC25 isoform was measured by realtime RT-PCR with the StepOne Plus System (Applied Biosystems) using specific primers and TaqMan ᭨ probes presented in Table 1 . Primers and probes were carefully designed to avoid self-complementarity or the formation of primer-dimers and hairpins. Reactions were performed using iTaq Supermix with ROX (Bio-Rad, Marnesla-Coquette, France), in a final volume of 25 mL with 0.4 mmol/L of each primer and 0.3 mmol/L of TaqMan ᭨ probe. The housekeeping gene, used to normalize each result, was the 18S rRNA (Eukaryotic 18S rRNA Endogenous Control, VIC/TAMRA Probe, Applied Biosystems). The real-time PCR program consisted of an initial denaturation step at 958C for 3 min followed by 45 cycles at 958C for 15 s and at 608C for 1 min. Each sample was analyzed in triplicate and each PCR experiment included at least one non-template control well. Gene expression was relatively quantified using the 2 -DDC T method (33) , where DDC T s(C T target gene -C T 18S rRNA ) cancerous cell line -(C T target gene -C T 18S rRNA ) non-cancerous cell line (hTERT-HME1), and C T represents the PCR cycle required to cross an arbitrarily placed threshold. Real-time PCR efficiencies were determined using serial dilutions of cDNA and calculated by the relationship Es10
(1/-slope) -1 ( Table 1) .
Statistical analysis
Data represent the mean of at least three independent experiments. Statistical analysis was performed using the Student's t-test. Differences between samples were considered as statistically significant for a p-value-0.05.
Results
Experiments were performed on different cell lines. The noncancerous mammary epithelial cell line hTERT-HME1, immortalized with the human telomerase reverse transcriptase, was used as a control relative to the mammary adenocarcinoma cell lines MCF-7 and MDA-MB231. These cell lines were obtained from pleural effusion of two different patients diagnosed with breast cancer and are considered as sensitive towards different anti-cancerous drugs. Moreover, two multidrug-resistant cell lines deriving from MCF-7 were compared to their sensitive MCF-7 counterpart: VCREMS selected as resistant to vincristine and DOXOR selected as resistant to doxorubicin, both exhibiting cross-resistance to a wide range of anti-cancerous agents.
CDC25 splice variants expression in breast cancer cell lines
The expression of the currently known CDC25 splice transcripts was first evaluated by semi-quantitative RT-PCR using primers adjacent to the region submitted to alternative splicing and designed in order to generate amplicons of different length specific for each CDC25 variant (Figure 1 ). Afterwards the contribution of the potentially major variants was evaluated through real-time, quantitative RT-PCR (qRT-PCR). For this purpose, we designed original primers and TaqMan ᭨ probes able to detect specifically each CDC25 variant (Table 1) . qRT-PCR efficiency was determined as 87%-100%, thus validating the primers and probe accuracy (Table 1) . Furthermore, primer specificity was verified since single amplicons of the expected size have been detected on agarose gel (data not shown).
CDC25A Two CDC25A splice variants were identified to date (23) , differing in the presence/absence of the exon 6 ( Figure 1A) . As shown by semi-quantitative RT-PCR, CDC25A1 is expressed in all tested cell lines, whereas CDC25A2 mRNA level is extremely low (Figure 2 ). With a more accurate qRT-PCR assay, a significant over-expression of global CDC25A (with an increase of both CDC25A1 and CDC25A2 variants) was observed in MDA-MB231 cell line compared to hTERT-HME1, but not in MCF-7 ( Figure 3A) . As MCF-7 and MDA-MB231 cell lines were obtained from two different patients, the expression level for the tested variants could depend on the tumor status. Additionally, global CDC25A, CDC25A1, and CDC25A2 expression is up-regulated in the resistant cell line VCREMS compared to the sensitive parental cell line MCF-7, whereas only the proportion of CDC25A2 is increased in DOXOR cells ( Figure 3A) . Consequently, CDC25A2 variant could be a resistance marker in these cells.
CDC25B CDC25B pre-mRNA alternative splicing generates at least five variants (24, 25) . CDC25B1-B4 transcripts diverge by differential incorporation of exons 2a, 6a, and 6b ( Figure 1B) . The CDC25B5 sequence is quite controversial The hybridizing position of each primer or probe is shown; e.g., Ex7 means that the primer is located within exon 7, jEx4-5 means that it is located at the junction between exons 4 and 5. Real-time PCR efficiency was determined as described in Materials and methods. mRNA levels of CDC25A, CDC25B, and CDC25C splice variants were evaluated by semi-quantitative RT-PCR using primers sets surrounding the region subject to alternative splicing (see Figure 1) . CDC25 splice variants levels in the indicated breast cancer cell lines were compared to those of the non-cancerous immortalized hTERT-HME1 cell line. Results are representative of two independent experiments.
(2), because it was found in only one study (25) , but is not listed in the Ensembl database. Thus, we chose not to study this variant. CDC25B3 represents the main variant in all studied cell lines, whereas CDC25B1, CDC25B2, and CDC-25B4 were expressed at lower levels ( Figure 2) . In order to obtain more rigorous data, we determined the expression level of global CDC25B, CDC25B1, and CDC25B2 by realtime PCR assay. CDC25B3 expression was not determined because it was impossible to design the primers and a TaqMan ᭨ probe specific for this variant with an amplicon length recommended for this kind of assay. The overall expression level of global CDC25B and CDC25B1 variant is quite similar in MCF-7 and MDA-MB231 cell lines relative to the normal cell line, whereas CDC25B2 is over-expressed, suggesting that this variant could be involved in the malignant transformation of these cells ( Figure 3B ). Resistant cell lines showed opposite results with VCREMS over-expressing CDC25B related isoforms, particularly CDC25B2, whereas DOXOR under-expressed them (compared to MCF-7) (Figure 3B) . Therefore, the CDC25B2 variant could be implicated in the acquisition of certain types of resistance.
CDC25C CDC25C pre-mRNA alternative splicing results into at least five variants exhibiting differential skipping of exons 3, 5, and 6 ( Figure 1C ) (23) . Semi-quantitative RT-PCR experiments showed that the major alternatively spliced transcripts correspond to the full-length CDC25C1 and to the shortest CDC25C5 variant, while other variants are present in lower amounts (Figure 2) . Interestingly, drug-resistant cell lines present particular profiles, since CDC25C5 and CDC-25C4 variants appear to be up-regulated in VCREMS, whereas CDC25C4 and CDC25C3 expression is increased in DOXOR, to the detriment of CDC25C1 (Figure 2 ). Quantitative RT-PCR demonstrated that global expression of CDC25C is constant in all cell lines, despite an unequal proportion of CDC25C splice variants ( Figure 3C ). CDC25C related variants expression is not statistically different in MCF-7 compared to hTERT-HME1, while MDA-MB231 cells present an increase of CDC25C1 and a decrease of CDC25C5 ( Figure 3C ). Most relevant, the ratio between CDC25C5 and CDC25C1 variants is increased in both resistant cell lines VCREMS and DOXOR compared to their sensitive cell line of origin MCF-7 (2.2"0.2 and 2.4"0.4-fold change, respectively) ( Figure 3D ). Therefore, CDC25C5/C1 ratio could represent a potential marker for multidrug-resistance development.
Discussion
CDC25 phosphatases are involved in cell cycle progression by activating cyclin/CDK complexes. Over-expression of CDC25A and CDC25B was documented in a variety of human malignancies (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) 34) , consistent with their oncogenic potential in cooperation with other oncogenic events (9) . Conversely, the implication of CDC25C in cancer remains enigmatic. Among the few studies having assessed CDC25C expression in cancer, some reported no implication of this isoform (18, 19, 34, 35) , while others observed an over-expression of CDC25C associated with aggressive cancer phenotypes (16, 21, 22, 36) . CDC25A up-regulation was reported particularly in breast cancer, often in association with a poor survival (9, 10, (12) (13) (14) , except for one study (11) . CDC25B over-expression was shown in two studies giving contradictory results. One of them showed a correlation between CDC25B up-regulation and severe histological grading (9) , whereas the other observed that CDC25B expression was significantly lower in aggressive breast tumors (11) . CDC25C expression has not been evaluated until now in breast cancer, except by Galaktionov et al. (9) . Nevertheless, they did not detect any expression of CDC25C in either normal tissues or tumoral ones.
These inconsistent results could be attributed to the lack of sensitivity of the techniques used or to the lack of exploration of the effective contribution of CDC25 alternative splicing (20) . In this context, we developed an original quantitative RT-PCR method and we report here the first sensitive and specific evaluation of CDC25 splice variants expression in breast cancer cells. We chose to work on two anti-cancerous drug-sensitive and two resistant cancer cell lines as well as on a non-cancerous mammary cell line, in order to highlight particular expression of CDC25 splice variants in these cells, and to suggest their possible implication in the tumorigenesis or in the drug resistance of breast cancer cells.
CDC25 pre-mRNA generates at least two alternative spliced transcripts for CDC25A and five for CDC25B and CDC25C (2). All these previously described splice variants were observed by semi-quantitative RT-PCR in our study, except CDC25B5. We showed that CDC25A2 variant mRNA level is very low compared to that of A1 in all mammary cell lines. Concerning CDC25B, CDC25B3 is the major variant both in normal and cancerous cells, which is consistent with previous studies (16, 19, 24, 25, 35) . Interestingly, CDC25B1 and CDC25B4 are expressed at a quite high level in all mammary cell lines tested, although they were previously reported as rare transcripts in other types of cell lines and tissues (16, 19, 25, 35) , suggesting that they may have some specific function in breast tissue. Moreover, in the present study, global CDC25C expression is constant between all cell lines, whereas splicing profiles are rather divergent. Full length CDC25C1 and the alternative spliced CDC25C5 variant are the most abundant transcripts in mammary cell lines, in agreement with previous studies (21, 23) . It is worth noting that additional CDC25C variants (CDC25C6-10) were identified recently in myelodysplastic syndromes (37) . Nevertheless, these variants seem to be expressed specifically in this type of malignancy, since they were not detected in previous studies as well as in our study, despite the use of the same RT-PCR primers.
In this study, we were particularly interested in the possible implication of CDC25 splice variants in multidrug resistance development. qRT-PCR assays showed that CDC25A2 variant, even if less expressed than CDC25A1, is up-regulated in drug-resistant VCREMS and DOXOR cell lines compared to their sensitive counterpart MCF-7 and could therefore be associated with the resistance phenotype of these cells. Exon 6 is skipped in CDC25A2 and the consequence of such a deletion is still unknown. However, this sequence contains multiple regulatory sites including a Chk1 phosphorylation site (Ser178) leading to cytoplasmic sequestration of CDC25A protein by interaction with 14-3-3 protein (38) . The absence of this site could increase CDC25A2 oncogenic potential. Moreover, we observed that CDC25B2 is highly over-expressed in the vincristine-resistant VCREMS cell line. Strikingly, doxorubicin-resistant DOXOR cells showed completely opposite results probably due to the distinct mode of resistance acquisition between these two cell lines (30, 32) . Overexpression of this transcript was previously found in poorly differentiated colorectal carcinomas and in aggressive nonHodgkin's lymphomas (16, 19) . Interestingly, in fission yeast, CDC25B2 is more efficient as an inducer of mitosis compared to CDC25B3 and CDC25B1 (24) . In fact, CDC25B2 is very stable throughout mitosis because it lacks the KEN box motif (exon 6a) recognized by the APC/C Cdh1 ubiquitin ligase complex and leading to the proteasome-mediated degradation of the protein (39) . Finally, CDC25C showed the most important particularities in resistant cells, i.e., a downregulation of CDC25C1 and an up-regulation of CDC25C5 and CDC25C4 variants. At the protein level, these last variants encompass 15 unique amino acids (23) corresponding to a putative CDK phosphorylation site. The role of this sequence is unknown, but it could be involved in drug-resistant phenotypes. Additionally, CDC25C3 level is up-regulated only in the DOXOR cell line. This transcript gives rise to a protein lacking the phosphatase activity, whose function is still unknown. Interestingly, the two-fold increase of the CDC25C5/C1 ratio observed by qRT-PCR in the two resistant cell lines relative to their sensitive counterpart can be considered as a more significant resistance marker than each CDC25C variant expression taken separately. The up-regulation of the alternatively spliced CDC25C5 mRNA was already reported in prostate cancer in correlation with biochemical recurrence (21) . This correlates with the increased uncoupling of mitosis from DNA replication observed with CDC25C5 compared to CDC25C1 (26) . Therefore, the expression of the CDC25C5 variant could potentially result in genomic instability and thus facilitate the emergence of more aggressive diseases, perhaps through poor regulation of its activity. Finally, these observations may call into question the lack of oncogenic potential reported for CDC25C (9) . In the future, the oncogenic potential of CDC25C should be evaluated considering each splice variant separately.
Breast cancer is the most frequent malignant tumor in women and, despite extensive progress in the clinical outcome of this disease, it still remains imperative to identify new powerful molecular biomarkers. In this context, splice variants have emerged as a novel source for clinical diagnostic and prognostic strategies (28) . For instance, Venables et al. (40) analyzed the alternative splicing profiles of 600 cancer-associated genes and identified 41 alternative splicing events significantly different between normal breast tissues and breast tumors. Five of them allowed classification of tumors according to their histopathologic grade. One of the best known cancer-related genes whose alternative splicing is of particular importance in cancer is the CD44 gene, coding for a transmembrane protein involved in cell-cell adhesion. For example, CD44v6 over-expression was shown to correlate with a higher grade in gastric cancer and with a lower survival rate for the patients (28) , suggesting that CD44 variants may be useful cancer biomarkers.
On the basis of these observations and the inconsistencies between studies discussed above concerning CDC25 expression and its correlation with clinical features, the consideration of CDC25 alternative splicing will probably improve their clinical interest. Indeed, the present study demonstrates the limitation of analyzing CDC25 expression without considering its alternative splicing, since we showed that CDC25 splice variants mRNA are differentially expressed in breast cancer cell lines. Particularly, our data suggest that CDC-25A2 and CDC25B2 variants and an increased CDC25C5/ C1 ratio may be associated to multidrug-resistance development in cancer cells. Thanks to the experimental assays developed in the present study, we are currently evaluating CDC25 splice variants expression in primary mammary tumors. If the preferential expression of certain CDC25 variants was confirmed, it could highlight the potential interest of these splice variants as new biomarkers for the diagnosis and prognosis of breast cancer, in addition to other markers routinely used in clinical practice. These results could also pave the way for new personalized therapeutic options for breast cancer based on the selective inhibition of the relevant CDC25 splice variants implicated.
